Toggle menu
Email: info@cellmosaic.com / Tel: 781-463-0002

Shop by Category

  • ADC and Other Drug Conjugate (ODC) Solutions
  • AqT® Reagents and kits
  • AqT® Digoxigenin Kits and Reagents
  • Services
  • Standards and Controls
  • Biotin and Streptavidin/Avidin
  • Enzyme
  • Antibody
  • Nucleic Acid and Oligo
  • Peptide and Protein
  • Small Molecule
  • Assay, Buffers and Others
  • Membrane Protein and GPCR Related
  • Solid Support

    • Shop by Brand

  • PerKit™
  • SepSphere™
  • AqT®
  • oxLink™
  • sxLink™
  • View all Brands
  • ADC and Other Drug Conjugate (ODC) Solutions
  • AqT® Reagents and kits
  • AqT® Digoxigenin Kits and Reagents
  • Services
  • Standards and Controls
  • Biotin and Streptavidin/Avidin
  • Enzyme
  • Antibody
  • Nucleic Acid and Oligo
  • Peptide and Protein
  • Small Molecule
  • Assay, Buffers and Others
  • Membrane Protein and GPCR Related
  • Solid Support

    • Shop by Brand

  • PerKit™
  • SepSphere™
  • AqT®
  • oxLink™
  • sxLink™
  • View all Brands

    • AqT® ADC Development & Manufacturing

    AqT® linkers are novel proprietary biomaterials invented at CellMosaic that are chemically assembled from a class of natural and edible sugar alcohol compounds with properties by design. AqT® linkers can be designed to label antibodies or proteins with very hydrophobic drugs to improve the overall performance of an ADC or PDC as a safer and more effective drug. 

    Benefit of AqT® ADC

      • Decreased toxicity
        • Less aggregated with no or limited precipitation
        • More biocompatible
      • Increased efficacy
        • Increase antibody stability (prevent enzymatic degradation of the antibody during circulation)
        • Less heterogeneous (increased label efficiency)
        • Retention of binding activities
        • Higher loading if necessary
      • Strong Intellectual Property (IP) position
        • The first company in the sugar alcohol IP space. Freedom of operation.
        • Patent protection for broad composition matters of AqT® molecules and their conjugates.
        • Worldwide issued patents. 

    AqT® ADC Development Path

    Early-stage evaluation of AqT® technologies

    To facilitate the Customer’s evaluation of CellMosaic’s AqT®-drug for Customer’s internal development and drug screening with short timeline and low cost, CellMosaic provides easy access to AqT® technologies without any license fee under CellMosaic's standard material transfer agreement (MTA). 

      • No accessing or license Fee for evaluation
        • Preparing AqT® ADC at CellMosaic with standard custom bioconjugation cost rate.
        • AqT® ADC are transferred under MTA.
        • Scale of the production: 1-3 mg (up to total 30 mg AqT®-ADC per drug) of Ab.
      • Selected AqT®-Drugs: AqT®-SN38 (CM81380), AqT®-VC-PAB-MMAE, AqT®-VC-PAB-Deruxtecan
      • Selected AqT® Linker and Linkage Chemistry: T4 linker for surface NH2 and reduced thiol labeling

    Full AqT® ADC development plan

    For Customers who wish to work from the beginning using AqT® technologies or after the completion of the early-stage evaluation, CellMosaic offers a flexible ways/term to work with for a full AqT® ADC development plan. 

      • Development partnership
      • Option to license
      • Joint-venture or equity partnership
      • Grant mechanism

    Full AqT® ADC Discovery, Development & Manufacturing (Process similar to standard ADC development & manufacturing)

      • No limitation of AqT® drugs.* 
      • No limitation of AqT® linker and linkage chemistry.*
      • No limitation of the reaction scale or production scale
      • License terms and technology transfer to be negotiated

    *: with compatible chemistry

    Compare Selected